MidLantic Urology (Site 0089)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Bladder cancer

Running trials

• Active, not recruiting

  Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

  NCT03924895· Phase 3· Merck Sharp & Dohme LLC· Source